TI-168

N/A

Report date: 2023/10/07 09:52:31

Base Information

Drug NameTI-168

Drug Alias NameTI-168

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tregs +[4]

Mechanisms of ActionCoagulation factor VIII modulators

TargetsCoagulation factor VIII

Therapy Area/IndicationsHemophilia A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesTeraImmune Inc

China Registration ClassN/A

Develop Information

Active CompaniesTeraImmune Inc

Inactive CompaniesN/A

Active IndicationsHemophilia A

Inactive IndicationsN/A

Other Information

ATC CodeN/A